However, reactivation of T cells through ICBs such as anti-PD-1 or anti-CTLA4 antibodies alone cannot antagonize all immune resistance mechanisms, and a significant proportion of patients with cancer do not respond to ICB treatment [19,20]. Here, CTLA4 is linked to cancer.